ANDA 212563

ANDA APPROVAL

Teva Pharmaceuticals USA, Inc.
Attention: Mahendra Barot
Director, Regulatory Affairs

Dear Mahendra Barot:

This letter is in reference to your abbreviated new drug application (ANDA) received for review on September 5, 2018, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Ferric Citrate Tablets, 210 mg.

Reference is also made to the tentative approval letter issued by this office on January 22, 2026, and to any amendments thereafter.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug meets the requirements for approval under the FD&C Act. Accordingly the ANDA is **approved**, effective on the date of this letter. We have determined your Ferric Citrate Tablets, 210 mg to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Auryxia Tablets, 210 mg, of Keryx Biopharmaceuticals, Inc. (Keryx) NDA - 205874.

The RLD upon which you have based your ANDA, Keryx's Auryxia Tablets, 210 mg, is subject to periods of patent protection. The following patents and expiration dates are currently listed in the Agency's publication titled *Approved Drug Products with Therapeutic Equivalence Evaluations* (the "Orange Book"):

U.S. Patent Number	Expiration Date
8,093,423 (the '423 patent)	April 21, 2026
9,387,191 (the '191 patent)	July 21, 2030
10,300,039 (the '039 patent)	July 21, 2030

Your ANDA contains paragraph IV certifications to each of the patents, under section 505(j)(2)(A)(vii)(IV) of the FD&C Act stating that the patents are invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Ferric Citrate Tablets, 210 mg, under this ANDA. You have notified the Agency that Teva Pharmaceuticals USA, Inc. (Teva) complied with the requirements of section

505(j)(2)(B) of the FD&C Act. Litigation was initiated within the statutory 45-day period against Teva for infringement of the '423 and '191 patents in the United States District Court for the District of Delaware [Keryx Biopharmaceuticals, Inc. and Panion & BF Biotech, Inc. v Teva Pharmaceutical USA, Inc., Civil Action No. 18-02012]. You have also notified the Agency that this case was dismissed.

Please note that if FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for a listed drug, an ANDA referencing that listed drug also will be required to have a REMS. See section 505-1(i) of the FD&C Act.

COMPENDIAL STANDARDS

A drug with a name recognized in the official United States Pharmacopeia or official National Formulary (USP-NF) generally must comply with the compendial standard for strength, quality, and purity, unless the difference in strength, quality, or purity is plainly stated on its label (see FD&C Act § 501(b), 21 USC 351(b)). FDA typically cannot share application-specific information contained in submitted regulatory filings with third parties, which includes USP-NF. To help ensure that a drug continues to comply with compendial standards, application holders may work directly with USP-NF to revise official USP monographs. More information on the USP-NF is available on USP's website as https://www.uspnf.com/.

REQUIREMENTS AND RECOMMENDATIONS POST APPROVAL

Under applicable statutes, regulations, and guidances, your ANDA may be subject to certain requirements and recommendations post approval, including requirements regarding changes to approved ANDAs, postmarketing reporting, promotional materials, and annual facility fees, among others. For information on post-approval requirements and recommendations for ANDAs and a list of resources for ANDA holders, we refer you to https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/requirements-and-resources-approved-andas.

Sincerely yours,

{See appended electronic signature page}

For Kendra S. Stewart, R.Ph., Pharm.D.
CAPT, United States Public Health Service
Director
Office of Regulatory Operations
Office of Generic Drugs
Center for Drug Evaluation and Research

Paul
Levine

Digitally signed by Paul Levine
Date: 3/11/2026 05:51:25AM
GUID: 56323ddc003554a87fad6698c2baa467